Abstract:Fatty acid synthase（FASN）is a protein encoded by FASN gene. As a key enzyme in de novo synthesis of fatty acids，FASN not only play a role in lipid metabolism，but also acts as an oncogene，which is abnormally expressed and can participate in the proliferation，differentiation，invasion and metastasis of various malignant tumors. In gynecological malignant tumors，abnormal elevation of FASN is significantly associated with poor prognosis of ovarian cancer，endometrial cancer，and cervical cancer. Current researches have proved that polyadenosine diphosphate - ribose polymerase（PARP）inhibitors combined with FASN inhibitors （denifanstat，TVB-2640）have obvious synergistic effects，which can significantly improve the therapeutic effect of high-grade serous ovarian cancer as well. This breakthrough may bring a new therapeutic method for advanced and recurrent gynecological malignancies.This article reviews the abnormal expression of FASN in gynecological malignant tumors and the development of FASN inhibitors，with a view to encouraging conventional detection of FASN clinically and more focus on the research of FASN inhibitors.